The application for the renewal of the approval of the active substance flonicamid (IKI-220) was submitted on 29 August 2017 and the rapporteur Member State informed the co-rapporteur Member State, the Commission and the Authority on 7 November 2017 that it had assessed the admissibility of the application pursuant to Article 3 of Implementing Regulation (EU) No 844/2012, and in particular its completeness and timeliness, and concluded that it was admissible. The application has been made public by the Authority. On 5 December 2023, the rapporteur Member State submitted the draft renewal assessment report to the Authority, which conducted a public consultation on it between 10 June and 9 August 2024. On 16 January 2025, the Authority requested additional information for the purposes of the renewal assessment pursuant to Article 13(3) of Implementing Regulation (EU) No 844/2012 and the applicant submitted that information on 14 February 2025 within the deadline given. On 9 March 2026, the Authority requested additional information for the purposes of assessment of the approval criteria concerning endocrine disrupting properties set out in points 3.6.5 and 3.8.2 of Annex II to Regulation (EC) No 1107/2009, as amended by Regulation (EU) 2018/605, pursuant to Article 13(3a) of Implementing Regulation (EU) No 844/2012 to be submitted by the applicant by 9 December 2027 and the submission is pending. The rapporteur Member State estimates that it will be able to submit the draft renewal assessment report to the Authority by the end of June 2029. The Authority estimates that it will be able to finalise its conclusion for flonicamid (IKI-220) by the end of March 2029, and as the Commission will need time to adopt the ensuing risk management decisions, the duration of the extension of the approval period should be set at 34 months and 15 days, until 15 October 2029.
Recital 30, Regulation (EU) 2026/2348
In force